Global Plasma Fractionation

Plasma Fractionation Comprehensive Study by Type (Immunoglobulins, Coagulation Factor Concentrates, Albumin, Protease Inhibitors, Others), Application (Immunology, Hematology, Neurology, Others), End user (Hospitals & clinics, Clinical Research Laboratories, Academic institutes) Players and Region - Global Market Outlook to 2028

Plasma Fractionation Market by XX Submarkets | Forecast Years 2023-2028 | CAGR: 7.1%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Plasma Fractionation
The Increasing effort to make procedures for fractioning proteins from plasma affordable is anticipated to drive the Global Plasma Fractionation market. Plasma is a blood component, derived from whole blood, and is used for various therapeutic and medical applications. Human plasma is a source of numerous different proteins, however, only a few of these proteins are useful for producing therapeutic plasma products. The process of separation, extraction, and purification of these proteins from the plasma is called as fractionation process. Plasma fractionation is the first process for large-scale protein purification, which was developed about 60 years ago by Cohn and co-workers. It is utilized in prevention as well as treatment of several severe diseases caused by immunologic disorders, trauma, and infections. Improved diagnostic facilities, and ease of access to improve healthcare along with the increasing incidences and prevalence of chronic diseases globally, are some factors responsible for the rising demand for plasma-derived products and is expected to drive the plasma fractionation market in the forecast period.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
CAGR7.1%


The market is highly fragmented by top players. The players are focussed on improving their product portfolio by extensively working on streamlining the technology used for fractionation processes. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

CSL Limited (Australia), Grifols, S.A. (Spain), Shire Plc. (Ireland), Octapharma AG (Switzerland), Kedrion S.P.A (Italy), Bio Product Laboratory (United Kingdom), Sanquin (Netherlands), The LFB Group (France) and Biotest AG (Germany) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Japan Blood Products Organization (Japan), China Biologic Products (China), Green Cross Corporation (South Korea), Shanghai RAAS Blood Products (China), Baxter International Inc.(United States), Hualan Biological Engineering Inc.(China) and China Biologic Products Holdings, Inc.(China).

Segmentation Overview
AMA Research has segmented the market of Global Plasma Fractionation market by Type (Immunoglobulins, Coagulation Factor Concentrates, Albumin, Protease Inhibitors and Others), Application (Immunology, Hematology, Neurology and Others) and Region. On the basis of Type, Immunoglobulin are dominating the market in the year 2022



On the basis of geography, the market of Plasma Fractionation has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2022. If we see Market by End user, the sub-segment i.e. Hospitals & clinics will boost the Plasma Fractionation market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Development of new plasma proteins therapies (Ceruloplasmin, IgA, Plasmin) leading to innovative treatments for the benefits of patients and Increased usage of recombinant proteins and products acting as a substitute for the plasma products.

Market Growth Drivers:
Increasing geriatric population & demand for plasma protein, Therapeutic applications of plasma-derived protein & its rising indications and Growing investment in R & D leading to new innovations in new plasma protein therapies.

Challenges:
Several pharmaceutical giants are developing a recombinant protein, which is anticipated to eat into the sales of plasma-derived proteins posing a challenge for the market.

Restraints:
Increasing market penetration by recombinant factors and Stringent regulations by the Government & reimbursement issues may hamper the growth of the market.

Opportunities:
Key vendors in the market are focusing on increasing the capacities of plasma fractionation and purification of a wide range of proteins, in turn providing an opportunity for the market.

Market Leaders and their expansionary development strategies
In November 2023, Grifols partnered with Versiti Blood Centers to optimize plasma collection and processing, aiming to further enhance the efficiency and sustainability of the plasma supply chain.
In October 2023, Grifols introduced Alpha1 Pro, a novel subcutaneous alpha-1 antitrypsin therapy for the treatment of Alpha-1 Antitrypsin Deficiency, offering a new delivery option for patients.


Key Target Audience
Plasma fractionation products manufacturers and distributors, Pharmaceutical and biotechnological companies, Healthcare service providers (including hospitals and clinics), Research and development (R&D) companies, Academic institutes, Government associations, Health insurance provider companies, Market research and consulting firms and Venture capitalists and investors

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Immunoglobulins
  • Coagulation Factor Concentrates
  • Albumin
  • Protease Inhibitors
  • Others
By Application
  • Immunology
  • Hematology
  • Neurology
  • Others
By End user
  • Hospitals & clinics
  • Clinical Research Laboratories
  • Academic institutes

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing geriatric population & demand for plasma protein
      • 3.2.2. Therapeutic applications of plasma-derived protein & its rising indications
      • 3.2.3. Growing investment in R & D leading to new innovations in new plasma protein therapies.
    • 3.3. Market Challenges
      • 3.3.1. Several pharmaceutical giants are developing a recombinant protein, which is anticipated to eat into the sales of plasma-derived proteins posing a challenge for the market.
    • 3.4. Market Trends
      • 3.4.1. Development of new plasma proteins therapies (Ceruloplasmin, IgA, Plasmin) leading to innovative treatments for the benefits of patients
      • 3.4.2. Increased usage of recombinant proteins and products acting as a substitute for the plasma products.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Plasma Fractionation, by Type, Application, End user and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Plasma Fractionation (Value)
      • 5.2.1. Global Plasma Fractionation by: Type (Value)
        • 5.2.1.1. Immunoglobulins
        • 5.2.1.2. Coagulation Factor Concentrates
        • 5.2.1.3. Albumin
        • 5.2.1.4. Protease Inhibitors
        • 5.2.1.5. Others
      • 5.2.2. Global Plasma Fractionation by: Application (Value)
        • 5.2.2.1. Immunology
        • 5.2.2.2. Hematology
        • 5.2.2.3. Neurology
        • 5.2.2.4. Others
      • 5.2.3. Global Plasma Fractionation by: End user (Value)
        • 5.2.3.1. Hospitals & clinics
        • 5.2.3.2. Clinical Research Laboratories
        • 5.2.3.3. Academic institutes
      • 5.2.4. Global Plasma Fractionation Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Plasma Fractionation (Price)
      • 5.3.1. Global Plasma Fractionation by: Type (Price)
  • 6. Plasma Fractionation: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. CSL Limited (Australia)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Grifols, S.A. (Spain)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Shire Plc. (Ireland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Octapharma AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Kedrion S.P.A (Italy)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bio Product Laboratory (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanquin (Netherlands)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. The LFB Group (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Biotest AG (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Plasma Fractionation Sale, by Type, Application, End user and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Plasma Fractionation (Value)
      • 7.2.1. Global Plasma Fractionation by: Type (Value)
        • 7.2.1.1. Immunoglobulins
        • 7.2.1.2. Coagulation Factor Concentrates
        • 7.2.1.3. Albumin
        • 7.2.1.4. Protease Inhibitors
        • 7.2.1.5. Others
      • 7.2.2. Global Plasma Fractionation by: Application (Value)
        • 7.2.2.1. Immunology
        • 7.2.2.2. Hematology
        • 7.2.2.3. Neurology
        • 7.2.2.4. Others
      • 7.2.3. Global Plasma Fractionation by: End user (Value)
        • 7.2.3.1. Hospitals & clinics
        • 7.2.3.2. Clinical Research Laboratories
        • 7.2.3.3. Academic institutes
      • 7.2.4. Global Plasma Fractionation Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Plasma Fractionation (Price)
      • 7.3.1. Global Plasma Fractionation by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Plasma Fractionation: by Type(USD Million)
  • Table 2. Plasma Fractionation Immunoglobulins , by Region USD Million (2017-2022)
  • Table 3. Plasma Fractionation Coagulation Factor Concentrates , by Region USD Million (2017-2022)
  • Table 4. Plasma Fractionation Albumin , by Region USD Million (2017-2022)
  • Table 5. Plasma Fractionation Protease Inhibitors , by Region USD Million (2017-2022)
  • Table 6. Plasma Fractionation Others , by Region USD Million (2017-2022)
  • Table 7. Plasma Fractionation: by Application(USD Million)
  • Table 8. Plasma Fractionation Immunology , by Region USD Million (2017-2022)
  • Table 9. Plasma Fractionation Hematology , by Region USD Million (2017-2022)
  • Table 10. Plasma Fractionation Neurology , by Region USD Million (2017-2022)
  • Table 11. Plasma Fractionation Others , by Region USD Million (2017-2022)
  • Table 12. Plasma Fractionation: by End user(USD Million)
  • Table 13. Plasma Fractionation Hospitals & clinics , by Region USD Million (2017-2022)
  • Table 14. Plasma Fractionation Clinical Research Laboratories , by Region USD Million (2017-2022)
  • Table 15. Plasma Fractionation Academic institutes , by Region USD Million (2017-2022)
  • Table 16. South America Plasma Fractionation, by Country USD Million (2017-2022)
  • Table 17. South America Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 18. South America Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 19. South America Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 20. Brazil Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 21. Brazil Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 22. Brazil Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 23. Argentina Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 24. Argentina Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 25. Argentina Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 26. Rest of South America Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 27. Rest of South America Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 28. Rest of South America Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 29. Asia Pacific Plasma Fractionation, by Country USD Million (2017-2022)
  • Table 30. Asia Pacific Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 31. Asia Pacific Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 32. Asia Pacific Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 33. China Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 34. China Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 35. China Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 36. Japan Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 37. Japan Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 38. Japan Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 39. India Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 40. India Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 41. India Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 42. South Korea Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 43. South Korea Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 44. South Korea Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 45. Taiwan Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 46. Taiwan Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 47. Taiwan Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 48. Australia Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 49. Australia Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 50. Australia Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 51. Rest of Asia-Pacific Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 52. Rest of Asia-Pacific Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 53. Rest of Asia-Pacific Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 54. Europe Plasma Fractionation, by Country USD Million (2017-2022)
  • Table 55. Europe Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 56. Europe Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 57. Europe Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 58. Germany Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 59. Germany Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 60. Germany Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 61. France Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 62. France Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 63. France Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 64. Italy Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 65. Italy Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 66. Italy Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 67. United Kingdom Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 68. United Kingdom Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 69. United Kingdom Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 70. Netherlands Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 71. Netherlands Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 72. Netherlands Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 73. Rest of Europe Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 74. Rest of Europe Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 75. Rest of Europe Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 76. MEA Plasma Fractionation, by Country USD Million (2017-2022)
  • Table 77. MEA Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 78. MEA Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 79. MEA Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 80. Middle East Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 81. Middle East Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 82. Middle East Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 83. Africa Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 84. Africa Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 85. Africa Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 86. North America Plasma Fractionation, by Country USD Million (2017-2022)
  • Table 87. North America Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 88. North America Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 89. North America Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 90. United States Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 91. United States Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 92. United States Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 93. Canada Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 94. Canada Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 95. Canada Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 96. Mexico Plasma Fractionation, by Type USD Million (2017-2022)
  • Table 97. Mexico Plasma Fractionation, by Application USD Million (2017-2022)
  • Table 98. Mexico Plasma Fractionation, by End user USD Million (2017-2022)
  • Table 99. Plasma Fractionation: by Type(USD/Units)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Plasma Fractionation: by Type(USD Million)
  • Table 110. Plasma Fractionation Immunoglobulins , by Region USD Million (2023-2028)
  • Table 111. Plasma Fractionation Coagulation Factor Concentrates , by Region USD Million (2023-2028)
  • Table 112. Plasma Fractionation Albumin , by Region USD Million (2023-2028)
  • Table 113. Plasma Fractionation Protease Inhibitors , by Region USD Million (2023-2028)
  • Table 114. Plasma Fractionation Others , by Region USD Million (2023-2028)
  • Table 115. Plasma Fractionation: by Application(USD Million)
  • Table 116. Plasma Fractionation Immunology , by Region USD Million (2023-2028)
  • Table 117. Plasma Fractionation Hematology , by Region USD Million (2023-2028)
  • Table 118. Plasma Fractionation Neurology , by Region USD Million (2023-2028)
  • Table 119. Plasma Fractionation Others , by Region USD Million (2023-2028)
  • Table 120. Plasma Fractionation: by End user(USD Million)
  • Table 121. Plasma Fractionation Hospitals & clinics , by Region USD Million (2023-2028)
  • Table 122. Plasma Fractionation Clinical Research Laboratories , by Region USD Million (2023-2028)
  • Table 123. Plasma Fractionation Academic institutes , by Region USD Million (2023-2028)
  • Table 124. South America Plasma Fractionation, by Country USD Million (2023-2028)
  • Table 125. South America Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 126. South America Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 127. South America Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 128. Brazil Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 129. Brazil Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 130. Brazil Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 131. Argentina Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 132. Argentina Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 133. Argentina Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 134. Rest of South America Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 135. Rest of South America Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 136. Rest of South America Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 137. Asia Pacific Plasma Fractionation, by Country USD Million (2023-2028)
  • Table 138. Asia Pacific Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 139. Asia Pacific Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 140. Asia Pacific Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 141. China Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 142. China Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 143. China Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 144. Japan Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 145. Japan Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 146. Japan Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 147. India Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 148. India Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 149. India Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 150. South Korea Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 151. South Korea Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 152. South Korea Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 153. Taiwan Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 154. Taiwan Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 155. Taiwan Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 156. Australia Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 157. Australia Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 158. Australia Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 159. Rest of Asia-Pacific Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 160. Rest of Asia-Pacific Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 161. Rest of Asia-Pacific Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 162. Europe Plasma Fractionation, by Country USD Million (2023-2028)
  • Table 163. Europe Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 164. Europe Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 165. Europe Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 166. Germany Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 167. Germany Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 168. Germany Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 169. France Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 170. France Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 171. France Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 172. Italy Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 173. Italy Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 174. Italy Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 175. United Kingdom Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 176. United Kingdom Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 177. United Kingdom Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 178. Netherlands Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 179. Netherlands Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 180. Netherlands Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 181. Rest of Europe Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 182. Rest of Europe Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 183. Rest of Europe Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 184. MEA Plasma Fractionation, by Country USD Million (2023-2028)
  • Table 185. MEA Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 186. MEA Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 187. MEA Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 188. Middle East Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 189. Middle East Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 190. Middle East Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 191. Africa Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 192. Africa Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 193. Africa Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 194. North America Plasma Fractionation, by Country USD Million (2023-2028)
  • Table 195. North America Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 196. North America Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 197. North America Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 198. United States Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 199. United States Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 200. United States Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 201. Canada Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 202. Canada Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 203. Canada Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 204. Mexico Plasma Fractionation, by Type USD Million (2023-2028)
  • Table 205. Mexico Plasma Fractionation, by Application USD Million (2023-2028)
  • Table 206. Mexico Plasma Fractionation, by End user USD Million (2023-2028)
  • Table 207. Plasma Fractionation: by Type(USD/Units)
  • Table 208. Research Programs/Design for This Report
  • Table 209. Key Data Information from Secondary Sources
  • Table 210. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Plasma Fractionation: by Type USD Million (2017-2022)
  • Figure 5. Global Plasma Fractionation: by Application USD Million (2017-2022)
  • Figure 6. Global Plasma Fractionation: by End user USD Million (2017-2022)
  • Figure 7. South America Plasma Fractionation Share (%), by Country
  • Figure 8. Asia Pacific Plasma Fractionation Share (%), by Country
  • Figure 9. Europe Plasma Fractionation Share (%), by Country
  • Figure 10. MEA Plasma Fractionation Share (%), by Country
  • Figure 11. North America Plasma Fractionation Share (%), by Country
  • Figure 12. Global Plasma Fractionation: by Type USD/Units (2017-2022)
  • Figure 13. Global Plasma Fractionation share by Players 2022 (%)
  • Figure 14. Global Plasma Fractionation share by Players (Top 3) 2022(%)
  • Figure 15. Global Plasma Fractionation share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. CSL Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 18. CSL Limited (Australia) Revenue: by Geography 2022
  • Figure 19. Grifols, S.A. (Spain) Revenue, Net Income and Gross profit
  • Figure 20. Grifols, S.A. (Spain) Revenue: by Geography 2022
  • Figure 21. Shire Plc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 22. Shire Plc. (Ireland) Revenue: by Geography 2022
  • Figure 23. Octapharma AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Octapharma AG (Switzerland) Revenue: by Geography 2022
  • Figure 25. Kedrion S.P.A (Italy) Revenue, Net Income and Gross profit
  • Figure 26. Kedrion S.P.A (Italy) Revenue: by Geography 2022
  • Figure 27. Bio Product Laboratory (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. Bio Product Laboratory (United Kingdom) Revenue: by Geography 2022
  • Figure 29. Sanquin (Netherlands) Revenue, Net Income and Gross profit
  • Figure 30. Sanquin (Netherlands) Revenue: by Geography 2022
  • Figure 31. The LFB Group (France) Revenue, Net Income and Gross profit
  • Figure 32. The LFB Group (France) Revenue: by Geography 2022
  • Figure 33. Biotest AG (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Biotest AG (Germany) Revenue: by Geography 2022
  • Figure 35. Global Plasma Fractionation: by Type USD Million (2023-2028)
  • Figure 36. Global Plasma Fractionation: by Application USD Million (2023-2028)
  • Figure 37. Global Plasma Fractionation: by End user USD Million (2023-2028)
  • Figure 38. South America Plasma Fractionation Share (%), by Country
  • Figure 39. Asia Pacific Plasma Fractionation Share (%), by Country
  • Figure 40. Europe Plasma Fractionation Share (%), by Country
  • Figure 41. MEA Plasma Fractionation Share (%), by Country
  • Figure 42. North America Plasma Fractionation Share (%), by Country
  • Figure 43. Global Plasma Fractionation: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • CSL Limited (Australia)
  • Grifols, S.A. (Spain)
  • Shire Plc. (Ireland)
  • Octapharma AG (Switzerland)
  • Kedrion S.P.A (Italy)
  • Bio Product Laboratory (United Kingdom)
  • Sanquin (Netherlands)
  • The LFB Group (France)
  • Biotest AG (Germany)
Additional players considered in the study are as follows:
Japan Blood Products Organization (Japan) , China Biologic Products (China) , Green Cross Corporation (South Korea) , Shanghai RAAS Blood Products (China) , Baxter International Inc.(United States) , Hualan Biological Engineering Inc.(China) , China Biologic Products Holdings, Inc.(China)
Select User Access Type

Key Highlights of Report


Jan 2024 211 Pages 95 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Plasma Fractionation Quantitative research analysis
Global Plasma Fractionation Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as CSL Limited (Australia), Grifols, S.A. (Spain), Shire Plc. (Ireland), Octapharma AG (Switzerland), Kedrion S.P.A (Italy), Bio Product Laboratory (United Kingdom), Sanquin (Netherlands), The LFB Group (France) and Biotest AG (Germany) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Development of new plasma proteins therapies (Ceruloplasmin, IgA, Plasmin) leading to innovative treatments for the benefits of patients " is seen as one of major influencing trends for Plasma Fractionation Market during projected period 2022-2028.
The Plasma Fractionation market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Plasma Fractionation Report?

Have a Query? Click Here

Other Related Reports

Endometriosis Therapies Comprehensive Study by Type (Hormonal Therapy (Oral Contraceptive Pills, Progestins), Hormone Replacement Therapy (GnRH Agonists, Luteinizing-hormone-releasing hormone recepto...
$ 3750
Thyroid Gland Disorder Treatment Comprehensive Study by Type (Medication, Surgery), Application (Men, Women), Diagnosis (Blood Tests, Imaging Tests, Physical Exams), Disorder Type (Hypothyroidism, Hy...
$ 3450
Lumbar Spine Fusion Comprehensive Study by Type (Anterior lumbar interbody fusion, Lateral lumbar interbody fusion, Posterior lumbar interbody fusion, Others), Application (Hospitals, Ambulatory Surg...
$ 3750
Liver Cirrhosis Comprehensive Study by Type (Alcoholic Cirrhosis, Atrophic Cirrhosis, Biliary Cirrhosis, Cardiac Cirrhosis, Cryptogenic Cirrhosis), Application (Hospitals, Specialty Clinics, Others),...
$ 3750
Simvastatin Comprehensive Study by Type (Enzymatic Synthesis, Chemical Synthesis), Application (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Form type (Tablet, Capsule) Players and Region - ...
$ 3500
Actinic Keratosis Treatment Comprehensive Study by Type (Flurouracil cream, Imiquimod cream, Ingenol Mebutate Gel, Diclofenac Gel), Application (Topical Surgery, Photodynamic Therapy, Other), Distrib...
$ 3450